HAT inhibition has been pursued as a therapeutic tool in the fight against cancer: bisubstrate inhibitors (mimicking the two HAT substrates, the acetyl-CoA and the lysine-containing peptide connected by a linker), natural compounds (anacardic acid, curcumin, garcinol), small molecule inhibitors (C646), and protein/protein interaction inhibitors are currently being investigated in different tumor types, despite such limitations as instability, low cell permeability, selectivity, and low potency [77]. This evidence concerns the gene TMPRSS11D and neoplasm.